Unlike the fi rst decade of AIDS treatment, most NCDs
can be treated with inexpensive, off -patent medicines.
Securing of global access to off -patent NCD medicines
would already be an enormous achievement with
profound eff ects on global health. However, access
should also be ensured, when needed now and in the
future, to newly developed, on-patent NCD medicines
and vaccines, such as the HPV vaccine